Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends

Pediatric Blood & Cancer, 04/27/2012

Bevacizumab–related acute toxicity appears to be low in children, even in combination with irinotecan. Further prospective trials are required to confirm the hypothetical efficacy of bevacizumab and to assess the risk of long–term toxicity especially in the youngest children.

Print Article Summary Cat 2 CME Report